Company intelligence / Profile preview

Jianersheng

Zhuhai, Guangdong, China

Ownership: Private
Development stage: Phase 1

Overview

Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd. develops small molecule therapeutics with a primary focus on chelating agents for treating heavy metal poisoning. Its lead candidate, GMDTC, has reached Phase 1 clinical trials in China targeting patients with excessive cadmium exposure. The company leverages advanced biotechnological methods and has experience in enzyme catalysis and metabolic engineering through its related entities. No commercialized products or late-stage assets are reported as of early 2025.

Therapeutic areas: Other
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

GMDTC

Phase 1

Indications: Heavy metal poisoning, Cadmium toxicity

Beyond the preview

Go deeper on Jianersheng.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jianersheng.

Explore the full profile